tiprankstipranks
Trending News
More News >
Ascentage Pharma Group International (HK:6855)
:6855
Hong Kong Market

Ascentage Pharma Group International (6855) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

Ascentage Pharma Group International has a market cap or net worth of HK$21.54B. The enterprise value is HK$5.19B.
Market CapHK$21.54B
Enterprise ValueHK$5.19B

Share Statistics

Ascentage Pharma Group International has 348,477,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding348,477,500
Owned by Insiders
Owned by Institutions

Financial Efficiency

Ascentage Pharma Group International’s return on equity (ROE) is -1.53 and return on invested capital (ROIC) is -17.43%.
Return on Equity (ROE)-1.53
Return on Assets (ROA)-0.15
Return on Invested Capital (ROIC)-17.43%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee1.73M
Profits Per Employee-715.05K
Employee Count567
Asset Turnover0.37
Inventory Turnover4.41

Valuation Ratios

The current PE Ratio of Ascentage Pharma Group International is -31.80. Ascentage Pharma Group International’s PEG ratio is >-0.01.
PE Ratio-31.80
PS Ratio0.00
PB Ratio3.51
Price to Fair Value48.81
Price to FCF-5.82
Price to Operating Cash Flow-6.80
PEG Ratio>-0.01

Income Statement

In the last 12 months, Ascentage Pharma Group International had revenue of 980.65M and earned -405.43M in profits. Earnings per share was -1.34.
Revenue980.65M
Gross Profit951.57M
Operating Income-378.80M
Pretax Income-395.25M
Net Income-405.43M
EBITDA-299.63M
Earnings Per Share (EPS)-1.34

Cash Flow

In the last 12 months, operating cash flow was -354.39M and capital expenditures -16.53M, giving a free cash flow of -370.92M billion.
Operating Cash Flow-354.39M
Free Cash Flow-370.92M
Free Cash Flow per Share-1.06

Dividends & Yields

Ascentage Pharma Group International pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.06
52-Week Price Change130.93%
50-Day Moving Average47.29
200-Day Moving Average41.46
Relative Strength Index (RSI)75.06
Average Volume (3m)3.97M

Important Dates

Ascentage Pharma Group International upcoming earnings date is Aug 26, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateAug 26, 2025
Ex-Dividend Date

Financial Position

Ascentage Pharma Group International as a current ratio of 1.26, with Debt / Equity ratio of 11.39%
Current Ratio1.26
Quick Ratio1.26
Debt to Market Cap0.13
Net Debt to EBITDA-1.36
Interest Coverage Ratio-5.88

Taxes

In the past 12 months, Ascentage Pharma Group International has paid 10.43M in taxes.
Income Tax10.43M
Effective Tax Rate-0.03

Enterprise Valuation

Ascentage Pharma Group International EV to EBITDA ratio is -44.39, with an EV/FCF ratio of -98.06.
EV to Sales13.56
EV to EBITDA-44.39
EV to Free Cash Flow-98.06
EV to Operating Cash Flow-119.45

Balance Sheet

Ascentage Pharma Group International has HK$1.26B in cash and marketable securities with ¥1.67B in debt, giving a net cash position of HK$407.29M billion.
Cash & Marketable SecuritiesHK$1.26B
Total Debt¥1.67B
Net CashHK$407.29M
Net Cash Per ShareHK$1.17
Tangible Book Value Per ShareHK$0.57

Margins

Gross margin is 85.56%, with operating margin of -38.63%, and net profit margin of -41.34%.
Gross Margin85.56%
Operating Margin-38.63%
Pretax Margin-40.31%
Net Profit Margin-41.34%
EBITDA Margin-30.55%
EBIT Margin-38.63%

Analyst Forecast

The average price target for Ascentage Pharma Group International is HK$52.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$52.00
Price Target Upside-16.60% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast330.23%
EPS Growth Forecast59.68%

Scores

Smart Score7
AI Score54
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis